Syneron Medical
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Syneron Medical missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP loss per share dropped.
Margins grew across the board.
Revenue details
Syneron Medical tallied revenue of $60.1 million. The five analysts polled by S&P Capital IQ looked for sales of $65.5 million on the same basis. GAAP reported sales were 5.5% higher than the prior-year quarter's $57.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
EPS came in at $0.03. The five earnings estimates compiled by S&P Capital IQ predicted $0.04 per share. GAAP EPS were -$0.06 for Q3 against -$1.14 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 53.2%, 260 basis points better than the prior-year quarter. Operating margin was -3.6%, 6,130 basis points better than the prior-year quarter. Net margin was -3.8%, 6,660 basis points better than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $72.7 million. On the bottom line, the average EPS estimate is $0.12.
Next year's average estimate for revenue is $268.8 million. The average EPS estimate is $0.24.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 719 members out of 753 rating the stock outperform, and 34 members rating it underperform. Among 199 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 191 give Syneron Medical a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is buy, with an average price target of $17.38.
- Add Syneron Medical to My Watchlist.